2900. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A Hurvitz 1, Roberto Hegg 2, Wei-Pang Chung 3, Seock-Ah Im 4, William Jacot 5, Vinod Ganju 6, Joanne Wing Yan Chiu 7, Binghe Xu 8, Erika Hamilton 9, Srinivasan Madhusudan 10, Hiroji Iwata 11, Sevilay Altintas 12, Jan-Willem Henning 13, Giuseppe Curigliano 14, José Manuel Perez-Garcia 15, Sung-Bae Kim 16, Vanessa Petry 17, Chiun-Sheng Huang 18, Wei Li 19, Jean-Sebastien Frenel 20, Silvia Antolin 21, Winnie Yeo 22, Giampaolo Bianchini 23, Sherene Loi 24, Junji Tsurutani 25, Anton Egorov 26, Y
Lancet. 2023 Jan 14;401(10371):105-117.
Link